Simulations Plus (SLP) Projected to Post Quarterly Earnings on Thursday

Simulations Plus (NASDAQ:SLP) is projected to release its earnings data after the market closes on Thursday, April 3rd. Analysts expect Simulations Plus to post earnings of $0.25 per share and revenue of $21.93 million for the quarter.

Simulations Plus Trading Down 2.9 %

SLP stock opened at $24.00 on Thursday. Simulations Plus has a 1-year low of $23.73 and a 1-year high of $51.22. The stock has a 50-day moving average price of $31.03 and a 200-day moving average price of $30.68. The firm has a market cap of $482.21 million, a PE ratio of 60.00 and a beta of 0.89.

Insiders Place Their Bets

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 19.40% of the company’s stock.

Analysts Set New Price Targets

SLP has been the topic of several recent analyst reports. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. KeyCorp increased their target price on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $49.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.